Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 6/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.38 |
| ▸ | ROS1 | P08922 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNK | O75909 | 2/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31147673 | 0.85 | LCK (0.46) | MAPK3ALKROS1EGFRULK1 | |
| SCHEMBL25005393 | 0.85 | LCK (0.46) | MAPK3ALKROS1EGFRULK1 | |
| SCHEMBL27238042 | 0.81 | ALK (0.39) | MAPK3ALKROS1EGFRCCNA2 | |
| SCHEMBL602415 | 0.80 | MAPK3 (0.40) | MAPK3ALKROS1EGFRULK1 | |
| SCHEMBL31147612 | 0.79 | MAPK3 (0.53) | MAPK3ALKROS1EGFRMAP3K7 | |
| SCHEMBL25004482 | 0.79 | MAPK3 (0.53) | MAPK3ALKROS1EGFRMAP3K7 | |
| SCHEMBL25005171 | 0.79 | ALK (0.39) | MAPK3ALKSTK17BSTK17AULK1 | |
| SCHEMBL25004486 | 0.78 | ROS1 (0.52) | MAPK3ALKROS1EGFRMAP3K7 | |
| SCHEMBL29904740 | 0.78 | ROS1 (0.52) | MAPK3ALKROS1EGFRMAP3K7 | |
| SCHEMBL29904725 | 0.78 | KDM4E (0.46) | MAPK3ALKROS1EGFRMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023014022-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | MAPK3 1318/4885ALK 176/4885ROS1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.